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Background. Immune activation persists despite suppressive antiretroviral therapy (ART) in human immunodeficiency virus 
(HIV) infection and predicts non-Acquired Immune Deficiency Syndrome (AIDS) comorbidities including cardiovascular disease. 
Activated platelets play a key role in atherothrombosis and inflammation, and platelets are hyperactivated in chronic HIV infection. 
Aspirin is a potent inhibitor of platelet activation through the cyclooxygenase-1 (COX-1) pathway. We hypothesized that platelet 
activation contributes to immune activation and that aspirin would reduce immune activation and improve endothelial function in 
ART-suppressed HIV-infected individuals.
Methods. In this prospective, double-blind, randomized, placebo-controlled 3-arm trial of 121 HIV-infected participants on 
suppressive ART for >48 weeks, we evaluated the effects of 12 weeks of daily aspirin 100 mg, aspirin 300 mg, or placebo on soluble 
and cellular immune activation markers, flow-mediated dilation (FMD) of the brachial artery, and serum thromboxane B2, a direct 
readout of platelet COX-1 inhibition.
Results. The 300-mg and 100-mg aspirin arms did not differ from placebo in effects on soluble CD14, interleukin (IL)-6, soluble 
CD163, D-dimer, T-cell or monocyte activation, or the other immunologic endpoints measured. Endothelial function, as measured 
by FMD, also was not significantly changed when comparing the 300-mg and 100-mg aspirin arms to placebo.
Conclusions. Aspirin treatment for 12 weeks does not have a major impact on soluble CD14, IL-6, soluble CD163, D-dimer, 
T-cell or monocyte activation, or FMD, suggesting that inhibition of COX-1-mediated platelet activation does not significantly 
improve HIV-related immune activation and endothelial dysfunction. Although future studies are needed to further identify the 
causes and consequences of platelet activation in ART-treated HIV infection, interventions other than COX-1 inhibition will need 
to be explored to directly reduce immune activation in treated HIV infection.
Keywords.  aspirin; CD14; HIV; platelets.
Advances in antiretroviral therapy (ART) have increased sur-
vival of the human immunodeficiency virus (HIV)-infected 
population; however, life expectancy remains shorter, and the 
incidence of many morbidities including cardiovascular disease 
(CVD), remains higher than the general population, particu-
larly among those who initiate ART at more advanced disease 
stages [1–3]. Although ART toxicities and traditional risk 
factors may contribute to increased risk, elevated markers of 
innate immune activation, inflammation, and thrombosis (eg, 
soluble [s]CD14, interleukin [IL]-6, D-dimer) independently 
predict morbidity and mortality and CVD [4–7].
Platelets are key mediators in hemostasis, thrombosis, and 
atherogenesis, but they may also contribute to inflammation [8]. 
Platelets express Toll-like receptors (TLRs) [9] and can become 
activated in response to proinflammatory cytokines or bacterial 
components [10–12], both of which are elevated in HIV infection 
[13, 14]. Increased platelet reactivity is associated with an increased 
risk of cardiovascular events [15–18], thus, antiplatelet therapy is 
recommended in those at high risk for or with known CVD.
Because platelets are activated in HIV infection and may 
contribute to immune activation [19–23], we hypothesized 
that blocking platelet activation with aspirin, an antiplatelet 
drug that irreversibly inhibits the cyclooxygenase-1 (COX-1) 
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pathway, might decrease immune activation, coagulation, and 
improve surrogate markers of CVD. A previous uncontrolled, 
open-label study showed that 1 week of low-dose aspirin 
reduced immune activation (eg, sCD14 and T-cell activation) in 
ART-treated HIV-infected patients [23]. The goals of this trial 
were to evaluate the longer-term immune effects of aspirin and 
its effects on endothelial function.
METHODS
Study Design
The AIDS Clinical Trials Group (ACTG) A5331 study was a dou-
ble-blind, randomized, placebo-controlled 3-arm trial in ART-
suppressed HIV-infected individuals who were not currently 
taking daily aspirin or nonsteroidal anti-inflammatory drugs. 
Participants were randomized to receive aspirin 100 mg, aspirin 
300 mg, or placebo for 12 weeks, and were followed for 4 weeks 
after treatment was stopped. Aspirin and placebo tablets were sup-
plied by Bayer Pharma AG, Germany. A permuted block randomi-
zation algorithm with the 3 treatments randomized in a 1:1:1 ratio, 
block size = 6, was generated by the ACTG Data Management 
Center (DMC), to determine the order of treatments. Unique sets 
of Study Identification Numbers (SIDs) were allocated to study 
sites. The ACTG DMC mailed out a prescription list to the site 
pharmacist (unblinded) containing a mapping of SID numbers 
to their corresponding treatment regimen. Participants were ran-
domized to a treatment based on the permuted blocks, which 
were dynamically generated by the randomization system. Once 
the treatment for a given participant was determined, the Subject 
Enrollment System assigned an SID number corresponding to 
this treatment regimen. The site pharmacist was provided the SID 
number and used the prescription list to determine the appropri-
ate treatment to dispense. Participants, care providers, and study 
team members were blinded. For the immunological studies, we 
collected blood samples 6 times: at pre-entry (1 day to 1 week 
before entry), entry (up to 3 days after randomization and on/
before the first dose of study drug), at 2 weeks of study drug, at 11 
weeks of study drug, at 12 weeks of study drug, and at 16 weeks, 4 
weeks after study drug was stopped. We collected blood twice, at 
pre-entry/entry and week 11 or 12 to enable us to average 2 meas-
ures at each timepoint and thereby minimize intrasubject varia-
bility in soluble markers of inflammation [24]. We evaluated the 
effects of aspirin on endothelial function by measuring flow-me-
diated diameter (FMD) of the brachial artery at entry, before the 
first dose of study drug, and after 12 weeks of treatment, while 
still receiving treatment. Participants underwent clinical evalua-
tions, detailed bleeding questionnaires, safety laboratory testing, 
and blood sample collection and storage at these visits. Serum 
specimens, ethylenediaminetetraacetic acid-treated specimens, 
and peripheral blood mononuclear cells (PBMCs) were cryopre-
served for batched assays. The primary endpoint of the study was 
the change over 12 weeks in sCD14, chosen because of its low 
intrasubject variability compared with other soluble markers (eg, 
IL-6) and significance as a predictor of morbidity and mortality.
Study Participants
We enrolled participants ≥18 years of age, with chronic HIV 
infection on suppressive ART (HIV ribonucleic acid [RNA] 
below the quantification limit for at least 48 weeks, transiently 
detectable blips <500 copies/mL were allowed if flanked by 
undetectable values). Major exclusion criteria included a his-
tory of gastrointestinal or central nervous system bleeding, 
recent severe illness, liver or kidney disease, uncontrolled dia-
betes, pregnancy or breast-feeding, and use of immunosuppres-
sive medications within 24 weeks of study entry. The study was 
conducted at 15 clinical research sites of the ACTG network. 
Institutional review boards at each site approved the study. All 
participants provided written informed consent. The trial was 
registered using Clinical Trials Registration NCT02155985.
Evaluations
Laboratory Evaluations
We measured plasma sCD14, D-dimer, IL-6, and sCD163 at 
pre-entry, entry, 2 weeks, 11 weeks, 12 weeks, and 16 weeks. We 
measured plasma kynurenine/tryptophan (KT) ratio, inflamma-
tory monocyte subsets, and cellular markers of T-cell activation 
and exhaustion at entry and 12 weeks [25]. Serum thromboxane 
(TXB2) is a direct measure of the capacity of platelets to synthesize 
TXA2, and we used it as a specific measure of the pharmacological 
effect of aspirin on platelets and as a surrogate marker of adher-
ence to the intervention. We measured serum TXB2 levels at entry, 
2 weeks, 12 weeks, and 16 weeks (4 weeks after stopping study 
drug). We measured urine 11-dehydrothromboxane (11dhTxB2) 
(corrected for creatinine clearance) at entry and 12 weeks as a 
secondary measure of aspirin effectiveness. Urine 11dhTxB2 is a 
measure of overall platelet activation and a nonspecific measure 
of total-body TXB2, because up to 30% of TXB2 excreted in the 
urine is derived from extraplatelet sources [26]. All blood spec-
imens were drawn and processed at the local sites. The PBMCs, 
plasma, and serum were shipped to Case Western Reserve 
University School of Medicine (Cleveland, OH) for central analy-
sis. Peripheral blood mononuclear cells were thawed and stained 
with Live/Dead Fixable Yellow (Invitrogen, Carlsbad, CA) and 
divided into 2 aliquots for staining of T cells and monocytes. Cells 
were then stained with CD3 PerCP (BioLegend, San Diego, CA), 
CD4 AF700, CD8 APC-H7, HLA-DR PE, CD38 APC, and PD-1 
BV421 (BD Biosciences, San Jose, CA) and with CD14 Pacific 
Blue, CD16 PE, and CD69 PE-Cy7 (BD Biosciences, San Jose, 
CA) and acquired on an LSRII flow cytometer (BD Biosciences, 
San Jose, CA), using FacsDiva software (BD Biosciences, San Jose, 
CA). Frequencies of activated (CD38+HLA-DR+) and exhausted 
(PD1+) CD4 and CD8 T cells and monocyte subsets (CD14/
CD16/CD69) were determined by gating based on isotype con-
trols using FacsDiva software. Levels of plasma sCD14, IL-6, 
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sCD163, serum TXB2 (R&D Systems, Inc., Minneapolis, MN), 
D-dimer (Diagnostica Stago, Asnières sur Seine, France), and 
urine 11dhTxB2 (Corgenix, Broomfield, CO) were measured by 
enzyme-linked immunosorbent assay. Urine creatinine (random) 
was measured using colorimetric analysis (Affiliated Medical 
Services, Wichita, KS). Plasma kynurenine and tryptophan lev-
els were measured by high-performance liquid chromatography 
(University of California, San Francisco, CA), and the KT ratio 
was calculated, as previously described [27].
Endothelial Function
Endothelial function was assessed by FMD of the brachial 
artery, a well established measure of endothelium-dependent 
vasodilation, as previously described [28, 29]. Participants were 
required to be fasting and to not use any tobacco-containing 
products for 8 hours before the study. Each study was recorded 
digitally and sent to the University of Wisconsin (Madison, WI) 
core ultrasound laboratory where data analysis was performed.
Statistical Analysis
The primary endpoint was the change in sCD14 levels from 
baseline (average of pre-entry/entry) to week 12 (average of 
week 11/week 12). Based on prior studies, a 0.07 log10 sCD14 
between-arm difference would be associated with a 25% 
decreased odds of a nonacquired immune deficiency syndrome 
event or nonaccidental death [6], suggesting it would be a clini-
cally significant reduction, and this guided the effect size for the 
study, which required 40 participants per study arm. Secondary 
endpoints included (1) changes from baseline to week 12 in solu-
ble markers of inflammation and coagulation (average of pre-en-
try/entry compared with average of week 11/week 12) and (2) 
changes from entry to week 12 in T-cell markers of activation 
and exhaustion, monocyte subsets, plasma KT ratio, serum 
TXB2 levels, urine 11dhTxB2 to urine creatinine ratio, and FMD.
To examine the biologic effects of aspirin, we used as-treated 
analyses, limiting the analysis to participants on treatment for 
the duration of the study and who had sCD14 data from baseline 
and week 12. Mean changes (log transformed when appropri-
ate) within treatment arms and mean differences between arms 
were estimated using a single regression model. If data were log 
transformed, the exponent of model estimates were used to esti-
mate geometric mean fold changes within arms and the percent 
difference in geometric mean fold changes between arms. To 
assess whether the treatment effects varied across baseline sub-
groups, regression models consisting of the treatment arm main 
effect, the baseline covariate of interest, and their interaction 
were used for each baseline covariate individually. We explored 
interactions by baseline factors (age, sex, smoking status, ART 
regimen containing 2 nucleoside reverse-transcriptase inhibi-
tors + integrase strand transfer inhibitor, sCD14, sCD163, IL-6, 
D-dimer, serum TXB2, urine TXB2, plasma KT ratio, T-cell acti-
vation and exhaustion, monocyte subset percentage, and FMD). 
Relationships among variables were assessed with Spearman 
correlations. All statistical tests were 2-sided with a nominal 
alpha level of 0.05 with no adjustment for multiple testing.
RESULTS
Characteristics of Participants
A total of 170 participants were screened and 121 participants 
were enrolled at 15 US sites between August 2014 and March 
2015. Reasons for screen failure are provided in Figure 1. Five 
participants did not complete the study treatment due to one 
of the following: protocol-defined toxicity of blood in stools 
170 screened
121 underwent randomization
40 allocated to
300 mg aspirin
38 analyzed per-protocol 38 analyzed per-protocol 37 analyzed per-protocol
None excluded from
per-protocol analysis
2 excluded from per-protocol
analysis: 1 bacterial pneumonia, 1
cellulitis
1 excluded from per-protocol
analysis: 1 cellulitis
2 discontinuted:1 Intolerance,
1Lost to follow up
1 discontinuted:1 Non-protocaol
toxicity
2 discontinuted:1 Protocaol
defined toxicity, 1 Clinician request
40 allocated to
placebo
49 not enrolled
7 Active illness
3 Did not return
8 Prohibited meds
5 Lab value out of  range
3 Not on ART for specified time
4 Not willing to participate
15 Other
6 HIV RNA out of  range
41 allocated to
100 mg aspirin
Figure 1. Study flow chart of screening, enrollment, study completion, and analysis. Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; RNA, 
ribonucleic acid.
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Table 1. Characteristics of Participants at Time of Enrollment Into the Studya
Characteristics
Treatment (N)
300 mg (N = 40) 100 mg (N = 41) Placebo (N = 40) Total (N = 121)
Age (median) 48 50 49 49
Q1, Q3 (38, 54) (46, 56) (42, 57) (42, 55)
Sex Male 32 (80) 31 (76) 35 (88) 98 (81)
Female 8 (20) 10 (24) 5 (13) 23 (19)
Race/ Ethnicity White Non-Hispanic 21 (53) 18 (44) 21 (53) 60 (50)
Black Non-Hispanic 11 (28) 19 (46) 11 (28) 41 (34)
Hispanic 7 (18) 4 (10) 8 (20) 19 (16)
Asian/Pacific Islander 1 (3) 0 (0) 0 (0) 1 (1)
CD4 (median) 573 629 642 599
Q1, Q3 436, 684 481, 856 436, 747 456, 777
Smoking Never 18 (46) 25 (61) 25 (64) 68 (57)
Previously 11 (28) 7 (17) 6 (15) 24 (20)
Currently 10 (26) 9 (22) 8 (21) 27 (23)
Statin use 7 (19) 6 (14) 6 (16) 19 (16)
ART ABC 2 (5) 1 (2) 4 (10) 7 (6)
INSTI + 2 NRTI 14 (35) 8 (20) 12 (30) 34 (28)
NNRTI + 2 NRTI 12(30) 23(56) 14 (35) 49 (40)
PI + 2 NRTI 12(30) 12(29) 16 (40) 40 (33)
Abbreviations: ABC, abacavir; ART, antiretroviral therapy; INSTI, integrase strand transfer inhibitor; N, number; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside 
reverse-transcriptase inhibitor; PI, protease inhibitor.
aData are presented as No. (%) or median (interquartile range: Q1, Q3).
Table 2. Soluble Markers and Platelet Markers at Baselinea
Markers
Treatment (N)
Total (N = 112)300 mg (N = 38) 100 mg (N = 38) Placebo (N = 36)
sCD14 (ng/mL) Mean (SD) 1933 (781) 2021 (611) 1864 (458) 1941 (631)
Min, Max 828, 4136 889, 3264 1195, 3088 828, 4136
Median 1652 2043 1851 1852
Q1, Q3 1402, 2169 1544, 2459 1538, 2108 1465, 2280
sCD163 (ng/mL) Mean (SD) 565 (276) 648 (369) 692 (470) 634 (379)
Min, Max 251, 1462 198, 1918 277, 2823 198, 2823
Median 470 571 584 551
Q1, Q3 356, 738 387, 794 418, 693 391, 731
IL-6 (pg/mL) Mean (SD) 1.53 (1.16) 1.61 (1.62) 2.28 (4.57) 1.80 (2.83)
Min, Max 0.39, 5.16 0.22, 9.36 0.22, 28.30 0.22, 28.30
Median 1.13 1.15 1.30 1.19
Q1, Q3 0.82, 1.73 0.85, 1.85 0.82, 2.16 0.83, 1.85
D-dimer (ng/mL) Mean (SD) 158 (75) 165 (83) 170 (96) 164 (84)
Min, Max 54, 403 49, 434 51, 406 49, 434
Median 147 137 145 145
Q1, Q3 108, 175 109, 208 107, 199 109, 192
Serum KT ratio (%) Mean (SD) 38.5 (9.2) 40.4 (13.0) 39.0 (9.2) 39.3 (10.6)
Min, Max 22.1, 57.6 21.1, 73.5 24.5, 62.6 21.1, 73.5
Median 37.1 36.8 37.7 37.3
Q1, Q3 31.4, 45.6 32.3, 49.0 31.1, 45.9 31.4, 46.4
Serum TXB2 (ng/mL) Mean (SD) 31.6 (34.5) 31.4 (21.6) 30.9 (23.4) 31.3 (26.9)
Min, Max 1.9, 144.0 1.7, 81.3 7.0, 130.8 1.7, 144.0
Median 19.1 30.4 27.0 25.4
Q1, Q3 12.4, 36.2 13.9, 41.2 13.2, 38.9 12.6, 38.8
Urine 11dhTxB2/creatinine 
ratio (pg/mg)
Mean (SD) 4552 (3271) 4637 (2869) 5488 (4421) 4855 (3513)
Min, Max 822, 13 852 429, 11 114 1016, 19 284 429, 19 284
Median 3496 3,545 4789 3829
Q1, Q3 1984, 6289 2527, 6452 1917, 8308 2122, 6683
Abbreviations: 11dhTxB2, 11-dehydrothromboxane; IL, interleukin; KT, kynurenine/tryptophan; Max, maximum; Min, minimum; Q, quartile; s, soluble; SD, standard deviation; TXB2, thromboxane.
aData are presented as mean with SD and median (interquartile range: Q1, Q3).
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(placebo), nonprotocol-defined low-grade toxicity of constipa-
tion/bloating (100  mg), clinician request not in best interest 
of patient (placebo), intolerance (300 mg), and lost to follow 
up (300 mg). Three additional participants were not included 
in the per-protocol analysis because they had serious bacterial 
infections (predefined exclusion, because of the known inflam-
matory effects) during the study period. Two participants in the 
aspirin 100 mg group were excluded: 1 had bacterial pneumo-
nia during week 8 of the study, and 1 had finger cellulitis diag-
nosed during week 13 of the study. One study participant in the 
placebo group had foot cellulitis during week 12 of the study 
(Figure 1). Baseline characteristics are summarized in Table 1: 
98 (81%) of the participants were male, 60 (50%) were non-
White, 27 (23%) were current smokers, 19 (16%) were on stat-
ins, 7 (6%) were on an abacavir-containing ART regimen, and 
34 (28%) were on an integrase inhibitor-containing regimen. 
Self-reported adherence to study drug was high with approx-
imately 90% of study participants reporting 100% adherence. 
Aspirin was safe and well tolerated. There were no study dis-
continuations due to serious adverse events. Plasma HIV RNA 
levels did not change during treatment and remained below the 
limits of quantification.
Impact of Aspirin on Thromboxane Levels
Baseline serum TXB2 and urine11dhTxB2 (corrected for cre-
atinine clearance) are summarized in Table  2. Serum TXB2 
log10-transformed data were used for analysis. Serum TXB2 lev-
els did not change significantly in the placebo group and were 
reduced at 2 weeks and 12 weeks in the 300-mg group and 100-
mg group and returned to baseline 4 weeks after stopping study 
drug, as summarized in Figure  2A. The estimated geometric 
mean fold change was 0.28 (95% confidence interval [CI], .20–
.38) in the 300-mg arm, 0.20 (95% CI, .15–0.28) in the 100-mg 
arm, and 1.21 (95% CI, .86–1.69) in the placebo arm. Compared 
with placebo, the 300-mg arm had a mean 76.7% (95% CI, 63.1–
85.3) greater reduction (P <  .001) and the 100-mg arm had a 
mean 83.1% (95% CI, 73.0–89.4) greater reduction (P < .001). 
The levels of urine 11dhTxB2 (corrected for creatinine clear-
ance) paralleled serum TXB2 changes as shown in Figure  2B. 
The estimated geometric mean fold change was 0.25 (95% 
CI, .19–.32) in the 300-mg arm, 0.23 (95% CI, .18–.30) in the 
100 mg arm, and 0.96 (95% CI, 0.71–1.30) in the placebo arm. 
Compared with placebo, the 300-mg arm had a 74.2% (95% CI, 
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cebo on soluble markers soluble (s)CD14, sCD163, D-dimer, interleukin (IL)-6; *, 
sCD163, increased with 300-mg daily aspirin (14.7%; 95% confidence interval 
[CI], 0.8–30.4; P =  .037) compared with placebo. (B) Effects of 12 weeks of aspirin 
300 mg, aspirin 100 mg, and placebo on flow cytometry markers of T-cell activation 
(CD4+CD38+HLA-DR+, CD8+CD38+HLA-DR+), T-cell exhaustion (CD4+PD1+, CD8+PD1+), 
and inflammatory monocyte subsets (CD14dimCD16+CD69+, CD14dimCD16−CD69+, 
CD14+CD16+, CD14+CD16+CD69+), shown as mean-fold change (95% CI) from baseline.
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61.5–82.7) greater reduction (P < .001) and the 100-mg arm had 
a 76.1% (95% CI, 64.2–84.0) greater reduction (P < .001), with-
out evidence for a dose-response effect.
Impact of Aspirin on Soluble Markers
Baseline soluble markers are summarized in Table  2. As 
shown in Figure 3A, the levels of sCD14 (our primary end-
point) did not change significantly during 12 weeks of aspi-
rin treatment compared with placebo, regardless of aspirin 
dose tested. The estimated geometric mean fold change was 
0.99 (95% CI, .94–1.04) in the 300-mg arm, 1.03 (95% CI, 
.98–1.08) in the 100-mg arm, and 0.97 (95% CI, .93–1.02) in 
the placebo arm. Compared with placebo, the 300-mg arm 
had a 1.4% (95% CI, −5.5 to 8.8) greater increase (P =  .70) 
and the 100-mg arm had a 5.5% (95% CI, −1.7 to 13.3) 
greater increase (P = .14). There was also no evidence for a 
difference in week 12 sCD14 changes between pooled aspirin 
arms and placebo (P = .28).
As shown in Figure  3A, plasma IL-6 and D-dimer levels 
did not change significantly between baseline and 12 weeks 
Table 3. Cellular Markers at Baselinea
 Cellular Markers
Treatment (N)
Total (N = 112)300 mg (N = 38) 100 mg (N = 38) Placebo (N = 36)
CD4+CD38+HLA-DR+ (%) Mean (SD) 12.9 (7.2) 11.4 (5.8) 11.7 (5.9) 12.0 (6.3)
Min, Max 3.3, 28.1 2.7, 28.3 3.4, 26.1 2.7, 28.3
Median 12.6 10.3 10.7 10.5
Q1, Q3 6.7, 17.6 6.4, 16.4 6.8, 13.9 6.7, 16.2
CD4+ PD-1+ (%) Mean (SD) 32.2 (9.7) 32.7 (10.6) 36.3 (15.0) 33.7 (12.0)
Min, Max 9.7, 49.9 13.8, 59.8 15.6, 71.0 9.7, 71.0
Median 33.5 30.3 33.1 32.4
Q1, Q3 26.4, 38.7 23.8, 41.5 24.5, 43.2 25.4, 40.4
CD8+CD38+ HLA-DR+ (%) Mean (SD) 12.6 (10.0) 10.3 (5.8) 11.0 (5.1) 11.3 (7.3)
Min, Max 2.5, 40.9 2.7, 25.7 3.0, 23.3 2.5, 40.9
Median 8.6 9.2 11.3 9.5
Q1, Q3 6, 18 6.1, 12.7 6.6, 13.7 6.5, 13.8
CD8+ PD-1+ (%) Mean (SD) 26.0 (10.6) 29.3 (10.2) 30.2 (12.7) 28.5 (11.2)
Min, Max 8.8, 46.4 9.1, 52.7 13.4, 56.7 8.8, 56.7
Median 24.1 30.2 29.3 27.9
Q1, Q3 17.2, 33.4 19.5, 37.5 20.9, 37.8 19.5, 35.2
CD14dimCD16+ (%) Mean (SD) 5.7 (3.4) 7.8 (5.2) 6.5 (4.3) 6.7 (4.4)
Min, Max 0.9, 15.3 1.1, 23.1 0.9, 17.9 0.9, 23.1
Median 4.8 5.8 6.1 5.7
Q1, Q3 3.5, 7.3 4.2, 11.7 3.2, 8.0 3.7, 8.1
CD14dimCD16+CD69+ (%) Mean (SD) 26.6 (17.9) 25.1 (16.8) 28.9 (17.2) 26.9 (17.2)
Min, Max 1.8, 72.0 3.3, 63.8 2.4, 63.3 1.8, 72.0
Median 23.9 24 28.6 24.9
Q1, Q3 11.2, 39.5 8.2, 38.9 14.7, 38.9 12.4, 38.9
CD14+CD16− (%) Mean (SD) 65.7 (20.8) 67.5 (18.0) 72.1 (16.4) 68.4 (18.5)
Min, Max 12.4, 91.0 20.0, 89.0 4.3, 94.6 4.3, 94.6
Median 73.5 72.2 74.1 73.5
Q1, Q3 50.2, 81.9 55.5, 79.6 64.6, 81.0 60.0, 80.3
CD14+CD16−CD69+ (%) Mean (SD) 50.2 (19.3) 52.2 (22.0) 58.0 (24.3) 53.5 (22.0)
Min, Max 4.5, 88.4 8.8, 84.0 6.3, 91.6 4.5, 91.6
Median 51.4 55.6 63.9 54.6
Q1, Q3 38.8, 65.2 35.9, 69.1 41.1, 80.6 39.5, 69.3
CD14+CD16+ (%) Mean (SD) 29.6 (21.7) 25.5 (18.7) 22.1 (17.4) 25.7 (19.4)
Min, Max 4.7, 85.5 6.3, 77.4 3.3, 94.7 3.3, 94.7
Median 20.3 17.5 21.0 20.1
Q1, Q3 13.2, 47.2 10.4, 40.5 9.2, 27.0 11.5, 32.6
CD14+CD16+CD69+ (%) Mean (SD) 55.3 (21.6) 53.7 (24.0) 59.1 (23.7) 56.0 (23.0)
Min, Max 6, 94 9.3, 86.4 11.0, 90.8 6, 94
Median 58.6 59.1 58 58.6
Q1, Q3 41.2, 70.8 30.2, 72.8 42.4, 80.9 41.9, 75.2
Abbreviations: Q, quartile; SD, standard deviation.
aData are presented as percent with mean (SD) and median (interquartile range; Q1, Q3).
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of aspirin treatment compared with placebo. The estimated 
geometric mean fold change in IL-6 at 12 weeks was 1.03 (95% 
CI, .87–1.21) in the 300-mg arm, 1.13 (95% CI, .96–1.33) in the 
100-mg arm, and 0.92 (95% CI, .78–1.09) in the placebo arm, 
without significant differences between groups. The estimated 
geometric mean fold change in D-dimer at 12 weeks was 1.08 
(95% CI, .97–1.19) in the 300-mg arm, 0.99 (95% CI, .89–1.10) 
in the 100-mg arm, and 1.02 (95% CI, .91–1.13) in the placebo 
arm, also without significant differences between groups. As 
shown in Figure 3A, the estimated geometric mean fold change 
in sCD163 between baseline and 12 weeks was 1.12 (95% CI, 
1.03–1.23) in the 300-mg arm, 1.03 (95% CI, .94–1.13) in the 
100-mg arm, and 0.98 (95% CI, .89–1.07) in the placebo arm. 
Soluble CD163 significantly increased with 300 mg daily aspi-
rin (14.7%; 95% CI, .8–30.4; P = .037) compared with placebo, 
whereas there was no significant change with 100 mg daily aspi-
rin (5.2%; 95% CI, −7.5 to 19.6; P = .44) compared with placebo.
Impact of Aspirin on Cellular Markers
Baseline cellular markers are summarized in Table 3. Because 
platelet activation induces a proinflammatory phenotype in 
circulating classical monocytes, with increased expression 
of CD16 [30], we tested whether aspirin might affect the fre-
quency of circulating monocyte subsets. The frequencies of 
classical (CD14+CD16−), intermediate (CD14+CD16+), and 
nonclassical (CD14dimCD16+) monocyte subsets did not change 
significantly during 12 weeks of aspirin treatment compared 
with placebo. We also found no evidence for a change in plasma 
KT ratio, T-cell activation, and exhaustion (Figure 3B, Table 4).
Impact of Aspirin on Flow-Mediated Dilation 
Flow-mediated dilation measurements in the 300-mg and 100-
mg aspirin arms did not change from baseline to week 12 com-
pared with placebo. At week 12, the mean change was −0.32% 
(95% CI, −1.17 to .54) in the 300-mg arm, −0.98% (95% CI, 
−1.85 to −0.11) in the 100-mg arm, and −0.20% (95% CI, −1.08 
to .69) in the placebo arm. Compared with placebo, neither the 
300-mg arm difference, −0.12% (95% CI, −1.34 to 1.11; P = .85), 
nor the 100-mg arm difference, −0.79 (95% CI, −2.03 to .45; 
P = .21), were statistically significant (Figure 4). See Table 5 for 
a complete listing of FMD parameters between baseline and 
12 weeks of study drug, including relative FMD (%), average 
diameter of brachial artery (mm), brachial artery flow (cubic 
centimeter [cc]/min), and average diameter of reactive hyper-
emia (cc/min).
Assessment of Interactions
Interactions of study drug effects with current smoking, sex, 
age, ART regimen, and baseline marker tertile were assessed, 
combining aspirin arms to improve power. These analyses were 
mostly unrevealing, but they did appear to show less of an aspi-
rin-mediated increase in sCD163 among current nonsmok-
ers (P = .036) and women (P = .031) and greater reductions in 
D-dimer among current smokers (P  =  .027). Compared with 
placebo at 12 weeks, the mean percentage change of D-dimer 
in current smokers taking aspirin (300-mg and 100-mg arms 
pooled) was −25.1% (95% CI, −44.3 to .8) and in nonsmokers 
taking aspirin (pooled arms) it was 8.9% (95% CI, −5.8 to 25.8) 
(P = .027). These differences were modest and have to be con-
sidered with caution in the setting of multiple hypothesis testing. 
Spearman correlations were also performed within the 2 aspirin 
groups for all variables. Baseline serum TXB2 correlated with 
urine 11-dhTxB2 (0.30; P  =  .014), as did the change in serum 
TXB2 with urine 11-dhTxB2 in response to aspirin therapy (0.41; 
P = .001). No other significant associations were found.
DISCUSSION
In this randomized, double-blind, placebo-controlled trial, 12 
weeks of aspirin treatment, at either 100 or 300 mg daily, failed 
to reduce plasma levels of sCD14 in virologically suppressed 
HIV-infected participants on ART. There were also no consist-
ent differences between the 300-mg or 100-mg aspirin arms 
Table 4. Effects of 12 Weeks of Aspirin on Markers of Immune Activation, Exhaustion, and KT Ratioa
Marker
Mean Change Difference
300 mg P Values 100 mg P Values
%CD14+CD16− 5.09 (−3.66 to 13.84) .25 −3.10 (−11.84 to 5.65) .48
%CD14+CD16−CD69+ 4.16 (−2.18 to 10.49) .85 −3.59 (−12.55 to 5.37) .43
%CD14+CD16+ −4.96 (−14.01 to 4.05) .28 3.07 (−5.96 to 12.10) .50
%CD14+CD16+CD69+ −1.05 (−10.04 to 7.94) .82 −5.50 (−14.59 to 3.40) .22
%CD14dimCD16+ −0.02 (−1.45 to 1.41) .96 0.12 (−1.31 to 1.54) .87
%CD14dimCD16+CD69+ −1.94 (−8.17 to 4.29) .54 −4.04 (−10.27 to 2.19) .20
%CD4+CD38+HLADR+ −1.42 (−2.98 to 0.05) .19 −0.91 (−3.06 to 1.25) .41
%CD4+PD1+ 0.28 (−1.63 to 2.20) .77 0.56 (−1.36 to 2.47) .56
%CD8+CD38+HLADR+ −0.67 (−3.09 to 1.75) .58 −0.99 (−3.41 to 1.43) .42
%CD8+PD1+ 0.56 (−1.38 to 2.50) .57 0.67 (−1.27 to 2.61) .50
KT ratio 1.71 (−1.52 to 4.94) .30 −1.34 (−4.61 to 1.93) .42
Abbreviations: CI, confidence interval; KT, kynurenine/tryptophan.
aData are presented as mean change difference (95% CI) vs placebo.
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versus placebo for FMD, D-dimer, or any of the other immu-
nologic endpoints.
These results differ from the previous open-label study show-
ing that 1 week of 81 mg daily aspirin reduced sCD14 in ART-
treated HIV-infected participants. Reasons for these disparate 
results are unclear. A  transient reduction in immune activa-
tion seems unlikely because there was also no evidence of a 
reduction in sCD14 in the current trial at week 2. The baseline 
sCD14 was higher in the previous uncontrolled trial; therefore, 
we hypothesized that aspirin effects on sCD14 might only be 
apparent in persons with a higher baseline sCD14, but we did 
not find any evidence for interaction by baseline level of sCD14 
in the current study. The previous uncontrolled trial also had 
a greater prevalence of tobacco smokers (56%) than our cur-
rent trial (23%). Nevertheless, we failed to identify consistent 
interactions between smoking and changes in immunologic 
endpoints by treatment arm in the current trial, with the excep-
tion of possibly greater aspirin-mediated reductions in D-dimer 
among smokers. Likewise, we did not see an appreciable change 
in IL-6, D-dimer, the proportional representation of mono-
cyte subsets, or T-cell immune activation overall. There was 
an increase in sCD163 in the aspirin 300-mg arm, suggesting 
potentially “increased” monocyte activation with high-dose 
aspirin. Because we did not see an increase in sCD14 or any 
other monocyte subsets in the aspirin 300-mg arm, it is likely 
that this difference was spurious. Although we cannot exclude 
other potential cardiovascular benefits of aspirin in this setting 
(ie, on thrombosis or atherosclerosis), endothelial function as 
assessed by FMD failed to improve after 12 weeks of either dose 
of aspirin in our current trial. Thus, although we cannot fully 
explain the different inferences from the prior uncontrolled trial 
of aspirin, our current placebo-controlled trial suggests that 
aspirin—at the common clinical doses assessed—is unlikely 
to have a clinically significant effect on immune activation or 
endothelial function in most ART-suppressed individuals.
It has been suggested that inflammation modifies platelet 
function, leading to increased platelet reactivity and reduced 
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Figure 4. Effects of 12 weeks of aspirin 300 mg, aspirin 100 mg, and placebo 
on flow-mediated dilation, shown as mean change (95% confidence interval [CI]). 
Abbreviation: FMD, flow-mediated dilation.
Table 5. FMD Parametersa
FMD Parameters
Treatment (N)
Total (N = 112)300 mg (N = 38) 100 mg (N = 38) Placebo (N = 36)
Relative FMD (%) week 0 Median 4.55 4.84 3.69 4.26
Q1, Q3 3.24, 5.76 2.94, 6.56 2.47, 5.32 2.63, 6.22
Relative FMD (%) week 12 Median 3.03 3.73 3.94 3.73
Q1, Q3 2.23, 5.26 2.48, 4.76 1.88, 5.26 2.23, 5.18
Average diameter of brachial artery (mm) week 0 Median 0.43 0.43 0.45 0.44
Q1, Q3 0.40, 0.48 0.39, 0.49 0.40, 0.47 0.40, 0.48
Average diameter of brachial artery (mm) week 12 Median 0.43 0.44 0.44 0.44
Q1, Q3 0.40, 0.48 0.40, 0.50 0.41, 0.47 0.40, 0.49
Brachial artery flow (cc/min) Median 133.13 165.36 130.33 141.84
week 0 Q1, Q3 106.94, 224.32 87.72, 227.36 95.61, 193.32 98.00, 224.32
Brachial artery flow (cc/min) Median 146.07 151.64 147.85 147.25
week 12 Q1, Q3 108.43, 245.52 78.38, 259.84 97.01, 201.38 94.10, 241.37
Average diameter of reactive hyperemia (mm) Median 0.45 0.45 0.46 0.46
90 sec, week 0 Q1, Q3 0.42, 0.50 0.41, 0.51 0.43, 0.49 0.42, 0.50
Average diameter of reactive hyperemia (mm) Median 0.45 0.45 0.46 0.46
90 sec, week 12 Q1, Q3 0.41, 0.50 0.43, 0.51 0.44, 0.50 0.43, 0.50
Relative hyperemia brachial flow (cc/min) week 0 Median 864.00 840.64 840.84 848.56
Q1, Q3 691.67, 1157.86 752.07, 1062.10 642.98, 1154.69 694.90, 1139.49
Relative hyperemia brachial flow (cc/min) week 12 Median 761.07 932.95 855.67 857.82
Q1, Q3 638.30, 1078.83 758.95, 1102.68 726.25, 1082.85 673.63, 1090.50
Abbreviations: cc, cubic centimeter; FMD, flow-mediated dilation; Q, quartile.
aData are presented as median (interquartile range: Q1, Q3).
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antiplatelet drug efficacy in persons with known CVD [16, 31–
33]. Several studies have shown that platelets are activated in 
HIV infection [19–23], and a previously reported study demon-
strated reduced aspirin drug efficacy in HIV-infected persons 
compared with healthy controls, with less of a reduction in 
urine 11dhTxB2 and less inhibition of platelet aggregation by 
aspirin [23]. Although the 300  mg and 100  mg aspirin arms 
in our study achieved a mean reduction of 70.1% and 83.1%, 
respectively, in serum TXB2 levels (both P <  .001 vs placebo), 
both groups had weaker aspirin-mediated reductions than are 
typically observed in historical HIV-uninfected, where a typical 
response to low-dose aspirin therapy is to reduce serum TXB2 
by >95% or to below a level of 5 ng/mL [34–36]. Analyzing fur-
ther, only 25% achieved a reduction in serum TXB2 >90% and 
49% achieved a reduction <5  ng/mL in the 300-mg arm and 
only 24% achieved a reduction in serum TXB2 >90% and 42% 
achieved a reduction <5 ng/mL in the 100-mg arm at 12 weeks.
Similarly to ART-treated HIV-infected persons, persons with 
diabetes mellitus type 2 have increased platelet activation and 
reduced antiplatelet drug efficacy. Although platelet activation 
and impaired antiplatelet response in diabetes is associated with 
poor glycemic control, inflammation, and increased platelet 
turnover [37, 38], the cause of platelet activation and impaired 
aspirin response in HIV infection is incompletely understood. 
We found a weak association between baseline serum TXB2 and 
baseline sCD14 (rho = 0.21, P = .081), suggesting HIV-related 
bacterial translocation as a potential contributor to platelet acti-
vation, via platelet-expressed TLR4 [39, 40], but we found no 
association between baseline serum TXB2 and baseline IL-6, 
sCD163, or D-dimer. We also found no association between the 
change in serum TXB2 in response to 12 weeks of aspirin ther-
apy and baseline sCD14, IL-6, sCD163, or D-dimer. 
CONCLUSIONS
Future studies are needed to identify the causes and conse-
quences of platelet activation and reduced antiplatelet drug 
efficacy in ART-treated HIV infection. These studies may have 
important clinical implications for the prevention and treat-
ment of CVD in patients with HIV infection. Until further data 
are available, the use of aspirin for the primary and secondary 
prevention of cardiovascular events in HIV-infected patients 
should be individualized and prescribed according to the cur-
rent guidelines for the general population [41, 42].
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